Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week data from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera, demonstrating sustained hematocrit control and safety.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u26053","jir_publication_date":"2025-12-08","jir_source_link":"[Placeholder]","jir_short_summary":"Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week data from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera, demonstrating sustained hematocrit control and safety.","jir_summary":"### Product and Service Overview\nRusfertide is a novel therapeutic agent that demonstrated sustained hematocrit control and clinical efficacy over 52 weeks in the Phase 3 VERIFY trial for patients with polycythemia vera (PV). Administered once weekly by self-injection in addition to standard therapy, 61.99% of patients maintained a clinical response without requiring phlebotomy. The safety profile was favorable, with local injection site reactions, anemia, and fatigue being the main adverse events. Currently, rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA, and its impact on fiscal year ending March 2026 earnings is expected to be minor.\n\n### Market Impact and Outlook\nRusfertide presents a potential new standard of care for PV patients struggling to control hematocrit levels with existing treatments. The long-term extension trial THRIVE confirmed sustained efficacy and safety, along with a significant reduction in the annual thrombosis rate. Takeda, in collaboration with Protagonist Therapeutics, is preparing a marketing authorization application to the U.S. FDA, expected to expand treatment options and improve quality of life for PV patients. This will strengthen Takeda\u2019s competitiveness in the oncology field and represents a strategically important business development.","jir_financial_highlights":"Durable Clinical Response Rate: 61.99% (Maintained through 52 weeks)\nAverage Hematocrit Level: Below 43% (Maintained through 52 weeks)\nIncidence of Serious Adverse Events: 8.19% (During the 52-week trial period)\nAnnual Thrombosis Rate: 0.7 events\/year (During THRIVE trial period) (Reduced from 9.2 events\/year prior to REVIVE trial initiation)","jir_category":"Strategy\/Investment,Other","jir_hashtags":"#TakedaPharmaceuticalCompanyLimited,#rusfertide,#NewProduct,#JapanStocks","jir_key_figures":"Product\/Service Name: rusfertide\nLaunch\/Start Date: Unknown\nTarget Market: Polycythemia Vera (PV) patient market, oncology sector\nDevelopment Stage: Phase 3 trial (VERIFY trial) and long-term extension trial (THRIVE trial) ongoing","jir_meta_title":"Takeda Announces Long-term rusfertide Data for Polycythemia Vera Treatment at ASH","jir_meta_description":"Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week Phase 3 VERIFY trial data of rusfertide in polycythemia vera patients, demonstrating sustained hematocrit control and safety.","jir_og_title":"Takeda Announces Long-term Data on rusfertide for Polycythemia Vera Treatment","jir_og_description":"Takeda Pharmaceutical Company Limited presented 52-week data from the Phase 3 VERIFY trial of rusfertide at the 67th Annual Meeting of the American Society of Hematology, showing efficacy in controlling hematocrit levels in polycythemia vera patients.","jir_og_image_url":"\/assets\/og\/company-product-announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-7090","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n